



*TFW B
Sequence*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Joel F. Habener

Appl. No.: 09/635,679

Filed: August 10, 2000

For: **Insulinotropic Hormones and Uses
Thereof**

Confirmation No.: 6862

Art Unit: 1645

Examiner: Minnifield, Nita M.

Atty. Docket: 0609.1090009/MAC/ALS

Amendment Under 37 C.F.R. § 1.312

Office of Patent Publication
2231 Crystal Drive, Room 907
Arlington, VA 22313-1450

Sir:

K
to enter
7/1/04
nmr

Submitted herein is an Amendment Under 37 C.F.R. § 1.312. This amendment is in response to an error identified by the Office of Patent Publication, and it is respectfully requested that the Office of Patent Publication exercise its delegated authority to waive the requirement of 37 C.F.R. § 1.312 by accepting this amendment which is being filed after the payment of the issue fee. Applicant respectfully submits that such waiver is proper. 1280 O.G. 918 (March 23, 2004).

It is believed that extensions of time are not required beyond those that may otherwise be provided for in documents accompanying this Amendment. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made; and
- (C) Starting on a separate sheet, the Remarks.